A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents-Reference-Cited by-同舟云学术

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

Published:2018-11-15 Issue:1 Volume:94 Page:74-79
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Short Nicholas J.¹^ORCID,Jabbour Elias¹^ORCID,Naqvi Kiran¹,Patel Ami¹,Ning Jing²,Sasaki Koji¹,Nogueras-Gonzalez Graciela M.²,Bose Prithviraj¹^ORCID,Kornblau Steven M.¹,Takahashi Koichi¹,Andreeff Michael¹,Sanchez-Petitto Gabriela³,Estrov Zeev¹,Dinardo Courtney D.¹^ORCID,Montalban-Bravo Guillermo¹,Konopleva Marina¹,Alvarado Yesid¹,Bhalla Kapil N.¹,Fiskus Warren¹,Khouri Maria¹,Islam Rubiul¹,Kantarjian Hagop¹^ORCID,Garcia-Manero Guillermo¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Department of Internal Medicine; The University of Texas Health Science Center at Houston; Houston Texas

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25318/fullpdf

Reference25 articles.

1. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia;Fenaux;J Clin Oncol.,2010

2. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer.,2006

3. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy;Jabbour;Cancer,2010

4. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure;Prebet;J Clin Oncol.,2011

5. Homoharringtonine and omacetaxine for myeloid hematological malignancies;Lu;J Hematol Oncol.,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EXABS-119-MDS An Update on Higher Risk Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2023-09

2. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms;Cancers;2023-07-27

3. Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities;Cancers;2023-04-21

4. Current Understanding of DDX41 Mutations in Myeloid Neoplasms;Cancers;2023-01-05

5. Applications of phytochemicals in cancer therapy and anticancer drug development;Recent Frontiers of Phytochemicals;2023